[CPD] CARACO PHARMA LAB > 17.85 +1.42 ( +8.64%) Open > 16.41 Volume > 412558
Caraco Pharmaceutical Laboratories, Ltd. develops, manufactures, and markets generic, prescription, and over-the-counter pharmaceuticals in the United States and Puerto Rico. Its products include Metroprolol Tartrate for hyper-tension; Paromomycin Sulfate, an antibacterial product; Salsalate for decongestant; Choline Magnesium Trisalicylate, Flurbiprofen, and Meloxicam for arthritis/NSAID; Clonazepam for seizure and panic disorders; Oxaprozin for rheumatoid disease; Tramadol Hydrochloride for opiate agonist/analgesic; and Metformin Hydrochloride, Glipizide, and Metformin Extended Release, for diabetes. The company also offers Meperidine Hydrochloride, an analgesic; Ticlopidine for reduction of incidence of strokes; Tizanidine for the management of muscle tone associated with spasticity; Digoxin for heart failure; Clozapine, an anti-psychotic; Midrin, a vascular and migraine headache suppressant; Baclofen for Skeletal Muscle Releaxan; Hydrochlorothiazide for hyper-tension; Nimodipine for cardiac, channel blocker; Zolpidem, a sedative hypnotic; and Ondansetron Injectible anti-nausea. In addition, Caraco provides anti-depressant products, such as Mirtazapin, Citalopram Hbr, and Fluvoxamine; and anti-convulsant products, such as Carbamazepine, Zonisamide, Extended Phenytoin, Gabapentin tablets, and Gabapentin capsules.
 |
